Recently, CMS proposed a new rule addressing pricing concerns due to PBMs. Read our summary to learn more.
Insurance companies or their pharmacy benefit managers (PBMs) often receive compensation after the point-of-sale that lowers the final net amount they pay for the drug.
While manufacturer price concessions still account for the largest category, CMS is currently focusing on pharmacy price concessions by proposing two main changes.